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High density lipoprotein (HDL) normally functions with lecithin:cholesterol 
acyltransferase (LCA T) to facilitate reverse cholesterol transport whereby excess 
cholesterol is removed from peripheral tissue sites, such as arteries. Cigarette smoke 
contains reactive chemicals which may modify HDL and, therefore, impair its 
antiatherogenic function in reverse cholesterol transport. We tested this hypothesis by 
first comparing modification of HDL by cigarette smoke extract (CSE) and acrolein, a 
potent reactive aldehyde known to be present in cigarette smoke. Both CSE and acrolein 
caused structural modification of HDL in a concentration-dependent manner, as 
evidenced by diminution of free amino groups, increase in electrophoretic mobility, and 
apolipoprotein crosslinking. We then evaluated the capacity of modified HDL to activate 
LCAT, which requires apolipoprotein A-1 as a cofactor, and also to stimulate cholesterol 
efflux from THP-1 monocytic cells. After incubation with either CSE or acrolein, HDL 
had decreased capacity to activate LCAT. The effects of CSE and acrolein were both 
time- and concentration-dependent. Incubation of HDL with 20% (v/v) CSE for 0.5-6 
hours caused a progressive decrease (21-48%) in the capacity ofHDL to activate LCAT. 
With the same range of incubation times, acrolein caused a 24-63% decrease in LCAT 
activation capacity ofHDL. After incubation with increasing concentrations of CSE (2.5-
20%) for 6 hours, HDL had a 21-59% decrease in LCAT activation capacity. Similarly, 
incubation of HDL with increasing concentrations (0.1-0.8 mM) of acrolein for 6 hours 
resulted in a 31-63% decrease in LCAT activation capacity. When present during 
incubation, both aminoguan.idine and glutathione totally prevented modification of HDL 
and suosequent decrease in LCA T activation capacity caused by acrolein. Both 
aminoguanidine and glutathione totally prevented the increase in electrophoretic mobility 
but not apolipoprotein crosslinking caused by CSE. Moreover, they each partially 
prevented the decrease in LCAT activation capacity caused by CSE. However, 
modification of HDL by either CSE or acrolein did not change its capacity to stimulate 
cholesterol efflux from the cells. The data suggest that reactive aldehydes are involved in 
the modification of HDL by CSE. But other reactive chemicals in cigarette smoke are 
also implicated. Furthermore, it is suggested that modification of HDL by cigarette 
smoke may impair HDL's function in reverse cholesterol transport. 
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CHAPTER I 
. INTRODUCTION 
Coronary heart disease (CHD) is the number one killer in the United States and 
cigarette smoking is the single most preventable cause of death. Each year, cigarette 
smoking claims more than 400,000 lives, and it also contributes to more than 20% of 
. 
death from heart disease in this country. 
The pathogenesis of atherosclerosis, a form of CHD, is not fully understood 
despite extensive investigation. Blood cholesterol associated with different lipoprotein 
species has been implicated in the pathogenesis and progression of atherosclerosis. 
Epidemiological data have revealed a positive relationship between the levels of low 
density lipoprotein {LDL) and the incidence of atherosclerosis, and a negative 
relationship between the levels of high density lipoprotein (HDL) and the incidence of 
atherosclerosis. Normally, LDL delivers cholesterol to peripheral tissues via the LDL 
receptor pathway [1 ], whereas HDL removes excess cholesterol from peripheral tissues 
via the reverse cholesterol transport pathway [2]. 
Modification of either LDL or HDL may compromise their biological functions 
and promote atherogenesis. Recent studies have implicated oxidative modification of 
LDL in the development of atherosclerosis [3 for review]. Oxidized LDL is more 
atherogenic than native LDL because it is avidly taken up by macrophages via scavenger 
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receptors. Unlike the LDL receptor pathway, the unregulated scavenger receptor pathway 
leads to accumulation of cholesterol and eventually the formation of foam cells, the 
presence of which marks the initial onset of atherosclerosis. HDL can be also oxidatively 
modified. Modification of HDL may impair its functions in reverse cholesterol transport 
and, therefore, accelerate the development of atherosclerosis. 
As an independent risk factor for atherosclerosis, cigarette smoking adversely 
affects the lipoprotein profile by increasing LDL and total blood cholesterol and 
decreasing HDL cholesterol [4]. Cigarette smoking may also increase the risk of 
atherosclerosis via another mechanism. Inhalation of toxic chemicals in cigarette smoke, 
such as free ~dicals and reactive aldehydes, may result in modification of lipoproteins. 
For example, cigarette smoke modifies LDL into a form that promotes foam cell 
formation from macrophages [5]. However, modification ofHDL by cigarette smoke and 
the biological consequences of HDL modification by cigarette smoke have not been 
systematically studied. 
In an attempt to further elucidate the higher risk of atherosclerosis in cigarette 
smokers, this study was undertaken to characterize the modification of human HDL by an 
aqueous extract of cigarette smoke, i.e. cigarette smoke extract (CSE), and to evaluate 
the impact of this modification on HDL-mediated reverse cholesterol transport. 
--- ~-- ----
Introduction 
CHAPTER II 
REVIEW OF LITERATURE 
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To facilitate full understanding of the rationale behind this research project, the 
literature review begins with a general discussion of the HDL-mediated reverse 
cholesterol transport pathway. The discussion focuses on the major components and their 
participation in different stages of reverse cholesterol transport. The second part of the 
review introduces the concept of lipoprotein modification and its implication in 
atherogenesis. The research findings by other researchers on oxidative modification of 
lipoproteins provide a solid scientific foundation to study lipoprotein modification by 
cigarette smoke. The third part of the review deals with previous work on lipoprotein 
modification by cigarette smoke. Modification of LDL by cigarette smoke is discussed in 
great detail because of its logical connection to HDL modification by cigarette smoke. 
Limited data on HDL modification by cigarette ~oke is also discussed with 
identification of the areas that need further research. In the final part of this review, 
studies on the inhibition of lecithin:cholesterol acyltransferase (LCA T) activity are 
discussed. The research in this area is informative to enable the design of a hypothesis-
driven stUdy anned at evaluating the possible mechanism of HDL modification by 
cig~ette smoke. 
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Overview of Reverse Cholesterol Transport 
Cholesterol has significant biological functions in the human body. Overall, it 
supports biosynthesis of cell membranes, steroid hormones and bile acids. However, 
excess cholesterol associated with peripheral tissues, such as arteries, is implicated in the 
pathogenesis of atherosclerosis. The body can use both endogenous and exogenous 
cholesterol. In contrast to celluiar cholesterol biosynthesis, cholesterol absorption in the 
intestine is not actively regulated.. Therefore, removal of excess cholesterol from 
peripheral tissues for transport to the liver and subsequent excretion via bile acids are 
critical processes for cholesterol homeostasis. 
The concept of reverse cholesterol transport was first postulated by Glomset in 
1968 (2] . Since then, extensive research has supported such a metabolic process to 
transport peripheral cholesterol back to the liver. Figure 1 provides an overview of an 
current understanding of the reverse cholesterol transport pathway. HDL, LCAT and 
cholesteryl ester transport protein (CETP) each play a central role in reverse cholesterol 
transport. HDL removes free cholesterol from peripheral tissues. LCAT converts 
cholesterol into cholesteryl esters that can be transferred to other lipoprotein species by 
CETP. Eventually, LDL and HDL deliver cholesterol to the liver by receptor-mediated 
and also receptor-independent pathways. 
The most important lipoprotein species participating in the reverse cholesterol 
transport pathway is HDL. HDL is a highly heterogeneous family of particles with 
hydrated densities ranging from 1.07 to 1.21 g/ml [6]. The general structure of a HDL 
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Figure L Schematic representation of the reverse cholesterol transport pathway. (1) Using 
Apo A-I as a cofactor, LCAT transfers a fatty acyl group from lecithin to free cholesterol 
and generates lysolecithin and cholesteryl ester. (2) HDL removes free cholesterol from 
peripheral cell membrane via cholesterol efflux. (3) CETP transfers cholesteryl ester to 
VLDL or LDL. (4) The liver takes up LDL and HDL via LDL and HDL receptors. 
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particle consists of a core of hydrophobic lipids (triglycerides and cholesteryl esters) 
surrounded by a shell of polar lipids (phospholipids and free cholesterol) and 
apolipoptoteins. Apolipoproteins A-I and A-ll are the major proteins in HDL. Other 
apolipoproteins, such as apolipoproteins A-IV, C, D and E, may also be present in certain 
HDL species. 
HDL is primarily synthesized in the liver and then secreted into the circulation 
[7]. The nascent HDL matures in the circulation by obtaining more lipid components 
from different sources including other lipoprotein species. Nascent HDL can also be 
derived in the circulation either from the surface of other lipoprotein species, such as very 
low density lipoprotein (VLDL) remnant, or by formation of a complex between 
apolipoproteins and phospholipids. Twelve HDL subclasses have been identified, based 
upon a variety of properties, including hydrated density, apolipoprotein composition and 
charge. These HDL particles have different sizes and either discoidal or spherical shapes. 
Heterogeneity of HDL is implicated. in removal of cellular cholesterol. Small, 
lipid-poor HDL particles which only contain apolipoprotein A-I as protein component are 
much more effective in removing cellular cholesterol than other HDL species [8]. The 
mechanism of cholesterol transfer from peripheral tissue membrane to HDL is still not 
fully elucidated. Two major hypotheses to explain the phenomenon of cholesterol eftlux 
from cell membrane to HDL have been proposed. 
The first hypothesis is that cholesterol eftlux is a simple diffusion process [9]. 
With limited aqueous solubility, free cholesterol can move between cell membranes and 
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blood plasma. However, this movement is a bidirectional exchange process. 
Thermodynamically, HDL is a much more effective acceptor of free cholesterol than 
other plasma components because it has a small size and an ideal phospholipid/protein 
ratio. When there is a chemical gradient of cholesterol between cells and HDL, net flux of 
free cholesterol may occur in either direction. 
The second hypothesis is that HDL-mediated cholesterol eftlux occurs via a 
receptor-depende.ut mechanism. An HDL-binding protein has been identified in many cell 
types, including fil;roblasts, hepatocytes and macrophages [10]. Enrichment of free 
cholesterol in cells increased abundance of HDL-binding protein on the cell surface and 
also cholesterol efflux by HDL [10,11]. It is believed that binding ofHDL to the receptor 
signals the cell to release free cholesterol to HDL via passive transport. 
Both hypothetical models recognize the importance of LCAT in facilitating 
cholesterol efflux from cellular membranes to HDL. LCAT is a plasma enzyme primarily 
associated with HDL [2]. Using HDL as substrate, LCAT catalyzes the transfer of a fatty 
acyl group from the sn-2 position of phosphatidylcholine to free cholesterol, generating 
lysophosphatidylcholine and cholesteryl esters as products. As a result, LCAT decreases 
surface cholesterol concentration and increases cholesterol concentration in the core of 
HDL. LCAT catalysis creates a concentration gradient necessary for cellular cholesterol 
to diffuse to HDL. In addition, the LCAT reaction represents the first step in remodeling 
HDL to form small, lipid-poor HDL. Other enzymatic steps in the remodeling process 
8 
include transfer of cholesteryl esters to triglyceride-rich lipoproteins by CETP and 
removal oftriglycerides by lipoprotein lipase. 
The contribution of CETP to reverse cholesterol transport is not limited to the 
remodeling of HDL. CETP catalyzes exchange of neutral lipids, particularly triglycerides 
and cholesteryl esters, among different lipoprotein species [12]. Under normal 
physiological conditions, CETP activity results in net transfer of cholesteryl esters from 
HDL to VLDL, and triglycerides from VLDL to HDL. VLDL is metabolized into LDL 
via lipoprotein lipase in the circulation. LDL can then deliver its cholesterol to the liver 
via the LDL receptor pathway [1]. Therefore, CETP apparently plays a role in cholesterol 
transport from plasma to the liver. 
HDL may also deliver cholesterol to the liver via a receptor-dependent pathway. 
Numerous studies have demonstrated the existence of so-called HDL-binding proteins. 
The determined sizes and proposed functions of HDL-binding proteins vary from these 
studies. However, a recent study identified a specific HDL receptor in the liver and 
nonplacental steroidogenic tissues [13]. This receptor binds HDL with high affinity and 
mediates selective uptake of cholesteryl esters possibly by retroendocytosis, during which 
apolipoproteins A-I and A-ll are not degraded. The identification of a cell surface HDL 
receptor provides an important mechanism for the final delivery of cell-derived 
cholesterol from plasma to the liver, and further demonstrates the critical role of HDL in 
reverse cholesterol transport. 
9 
Lipoprotein Modification and Atherosclemsjs 
Although high blood LDL and low blood HDL are the major risk factors for 
atherosclerosis, cholesterol accumulation in arterial wall cannot be fully explained by 
blood lipoprotein levels alone. During the past decade, intensive research has focused on 
oxidative modification of LDL. It is now widely accepted that LDL becomes fully 
atherogenic only after being modified. Lipoprotein modification in general may provide a 
biochemical basis for the development of atherosclerosis. 
It has long been known that LDL can be chemically modified in vitro. However, 
Goldstein and colleagues [14] were the first to find that acetylated LDL, a form of LDL 
modified chemically by acetylation, is recognized and taken up by 
monocytes/macrophages at a rate many times that of normal LDL. The receptor 
responsible for this uptake is distinct from the classical LDL receptor, and is recognized 
as a so-called scavenger receptor. This scavenger receptor is expressed in large amounts 
in monocytes/macrophages, and is not down-regulated by the cellular cholesterol content 
as is the LDL receptor. Therefore, unregulated uptake of modified LDL by 
monocytes/macrophages will eventually lead to the formation of foam cells, which is the 
hallmark of early development of atherosclerosis. 
The scavenger receptor is also ~ble to recognize and take up other chemically 
modified forms of LDL, including acetoacetyl LDL and malondialdehyde-conjugated 
LDL [3] .. Oxidation of LDL can be induced by incubation with transition metal such as 
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copper and iron, and the oxidized LDL is also reco~d and taken up by the scavenger 
receptor. 
The concept of biological, as opposed to chemical, modification of LDL initially 
came from a study in which LDL was incubated with cultured endothelial cells [15]. 
Under such conditions, LDL undergoes oxidative modification similar to that induced by 
transition metals. To date, it is known that LDL can be oxidatively modified by all the 
major cells of the arterial wall, including endothelial cells, smooth muscle cells, and 
monocyte-derived macrophages. Regardless of the type of oxidative modification, LDL 
undergoes profound structural changes, and assumes certain properties that normal LDL 
does not have [3]. 
The initial step of oxidative modification involves the peroxidation of 
polyunsaturated fatty acids in LDL [16]. During oxidative modification of LDL, lipid 
peroxidation proceeds as naturally occurring antioxidants, such as vitamin E, are 
depleted. There is a loss of polyunsaturated fatty acids and formation of aldehydic lipid 
peroxidation products [17]. The reactive fragments from lipid peroxidation, such as 
malondialdehyde, can form adducts with apolipoprotein B-1 00 via lysine e-amino groups. 
As a result, there is neutralization of the positively charged region of LDL, disrupting the 
recognition ofLDL by the LDL receptor. 
Free radicals are also able to oxidize LDL cholesterol and fragment 
apolipoprotein B-1 00 [18, 19]. In addition, phosphatidylcholine is extensively degraded 
to lysophosphatidylcholine as oxidized LDL is formed [16]. The degradation may be due 
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to an intrinsic phospholipase A2 activity of apolipoprotein B-1 00 [20]. 
Lysophosphatidylcholine is cytotoxic and chemotactic for circulating human monocytes 
[21]. These physicochemical changes are important cues leading to oxidatively-modified 
LDL being taken up avidly by macrophages via scavenger receptors. 
There is evidence indicating that modification of LDL does happen in vivo. 
Oxidized LDL has been identified in atherosclerotic plagues from humans and Watanabe 
Heritable Hyperlipidemic (WlffiL) rabbits by using anti-malondialdehyde-LDL 
antibodies [22]. In coronary heart disease patients, oxidized cholesterol was found to be 
significantly increased in LDL, relative to the LDL of control subjects [23]. Other 
evidence for the role of oxidized LDL in atherogenesis comes from studies demonstrating 
that the antioxidant, probucol, can inhibit atherosclerotic lesion formation in WHHL 
rabbits and also cholesterol-fed rabbits [24]. 
By analogy, oxidative modification of HDL has also been studied intensively. 
Incubation of HDL with copper induces lipid peroxidation of polyunsaturated fatty acids. 
As a result, oxidized HDL had significantly increased levels of conjugated dienes and 
thiobarbituric acid-reactive substances (TBARS) [25-27], which are intermediate- and 
end-products of lipid peroxidation. Similar to LDL, HDL lost significant amounts of 
intact lysine and tyrosine residues upon oxidative modification [28]. HDL also had 
increased electrophoretic mobility on agarose gel [26, 28], presumably via the 
neutralization of positively charged amino residues of apolipoproteins. 
12 
In contrast to LDL oxidation, oxidative modification of HDL does not result in 
fragmentation of apolipoproteins. Instead, there is cross-linking of apolipoproteins as 
demonstrated by several studies [26, 28]. The nature of apolipoprotein cross-linking in 
oxidized HDL is not fully understood. However, dimeri.zation among different amino 
residues ·may be the result of oxidation or linkage with products of lipid peroxidation, 
such as reactive aldehydes. One study also suggested that there was proteolytic 
degradation of apolipoprotein A-I during oxidation [25]. 
Many studies also examined the biological functions of HDL in reverse 
cholesterol transport after oxidative modification of HDL. One study demonstrated that 
HDL lost much of its capacity to activate LCAT after being oxidatively modified by 
copper [28]. Another study showed that oxidized HDL formed by either copper- or 
gamma radiolysis-generated oxyradicals had decreased ability to stimulate cholesterol 
efflux from cholesterol-loaded fibroblasts [29]. In two other studies, researchers 
generated foam cells by loading mouse peritoneal macrophages with acetylated LDL, and 
found that copper-oxidized HDL lost its capacity to stimulate cholesterol efilux from 
these foam cells [25, 26]. Yet another study demonstrated that incubation of human 
monocytes with copper-oxidized HDL increased intracellular cholesterol content [30]. 
The researchers of this study reported that in concurrence with its reduced capacity in 
promoting cholesterol efilux, oxidized HDL was recognized and degraded by scavenger 
receptors. Therefore, accumulation of intracellular cholesterol of monocytes/macrophages 
could result from decreased efilux together with increased cholesterol uptake by the cells. 
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HDL can be also modified chemically by many other compounds. Reactive 
aldehydes are a class of such compounds that have been studied because of their 
physiological relevance. Modification of HDL by reactive aldehydes, such as 
malondialdehyde, caused structural changes that are similar to those occurring upon HDL 
oxidation. These changes include decreased lysine and tryptophan amino residues, 
increased TBARS and agarose gel electrophoretic mobility, and the formation of cross-
linked apolipoproteins [28]. More importantly, aldehyde-modified HDL has impaired 
ability to activate LCAT and to stimulate cholesterol efflux from cholesterol-laden cells 
[28,31]. 
Another chemical crosslinker that has been widely used in studying the function 
of HDL is tetranitromethane (lNM). TNM specifically modified tyrosine amino residues 
of HDL apolipoproteins and caused apolipoprotein cross-linking [26, 32]. It also 
appeared to induce lipid peroxidation and cause lipid degradation of HDL. The modified 
HDL had increased electrophoretic mobility on agarose gel. In addition, cross-linking of 
apolipoproteins by 1NM led to a loss of ligand binding activity of HDL to both 
macrophages and fibroblasts, coincident with reduced ability of HDL to promote 
cholesterol efflux from these cells. 
Modification of Lipoproteins by Cj~arette Smoke 
Cigarette smoke is noxious in that it contains many free radicals including 
hydroxyl radicals and alkoxyl radicals [33]. In addition to its adverse effects on the blood 
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lipid profile, cigarette smoking is speculated to promote atherogenesis by inducing 
oxidative modification ofLDL. 
Cigarette smoking was demonstrated to render LDL more susceptible to 
peroxidative damage and enhance the metabolism of LDL by macrophages [34, 35]. 
Macrophage-mediated lipid peroxidation of LDL isolated from blood of cigarette 
smokers was significantly increased in comparison to macrophage-treated LDL from 
nonsmokers. The uptake of LDL isolated from smokers by macrophages was also 
significantly increased. Supplementation of cigarette smokers with the antioxidant 
vitamin C decreased the susceptibility of their LDL-to copper-induced oxidation [36]. 
Some in vitro studies have examined the mechanism o( LDL modification by 
cigarette smoke. Yokode and colleagues reported that rabbit LDL treated with an aqueous 
cigarette smoke extract (CSE) migrated further on agarose gel after electrophoresis than 
native LDL [5]. The treated LDL also showed extensive fragmentation of apolipoprotein 
B-1 00 on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
metabolism of treated LDL by macrophages was significantly increased, which led to 
massive accumulation of cholesteryl esters in macrophages. However, TBAR.S levels did 
not increase in treated LDL, indicating lipid peroxidation was not involved in the 
modification of LDL by CSE. Superoxide dismutase, but not catalase, partially inhibited 
these changes. The authors concluded that superoxide anion produced in CSE might 
directly damage the protein moiety ofHDL. 
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In another study, lipid peroxidation in human plasma was detected after the 
plasma was exposed to gas phase cigarette smoke that had been passed through a 0.02 fliil 
filter [3 7]. There was also a slight increase of electrophoretic mobility of plasma LDL on 
agarose gel. These changes were only found after endogenous ascorbate was depleted, 
and exogenous ascorbate was able to delay such effects. 
. 
Whole cigarette smoke, however, did not induce lipid peroxidation of LDL in 
plasma in the absence of ascorbate, nor did it change electrophoretic mobility of LDL. 
Nevertheless, structural modification of plasma proteins by whole cigarette smoke was 
found as measured by protein carbonyl formation [38]. Such modification was partially 
inhibited by glutathione, but not ascorbate. The investigators suggested that phenolic 
compounds in whole cigarette smoke actually protected LDL from lipid peroxidation by 
arresting free radicals, and that the protein modification as detected by carbonyl 
formation could be caused by reactive aldehydes in cigarette smoke. 
A recent study by the author found that CSE did not cause oxidative modification 
of LDL [39]. Our data suggested that CSE possesses antioxidant activity and actually 
inhibited oxidative modification of LDL caused by either copper or a peroxyl-radical 
generating compound, 2,2'-azobis (2-amidinopropane) hydrochloride (AAPH). A low 
concentration of CSE (025%, in the final incubation volume) inhibited the formation of 
TBARS when LDL was incubated with copper. CSE also prevented copper- and AAPH-
induced . degradation of phosphatidylcholine to lysophosphatidylcholine and 
fragmentation of apolipoprotein B-100. In addition, CSE partially blocked the increased 
16 
electrophoretic mobility of LDL, as well as the loss of immunoreactivity of 
apolipoprotein B-1 00 against a murine monoclonal antibody caused by treatment with 
either copper or AAPH. Despite the apparent antioxidant potential of CSE that protected 
LDL against copper- and AAPH-mediated oxidation, CSE itself did induce modification 
of LDL. When LDL was incubated with CSE alone, structural modification of 
apolipoprotein B-100 was indicated by a slight increase in electrophoretic mobility, slight 
decrease of immunoreactivity with the monoclonal antibody against apolipoprotein B-
1 00, and marked increase of protein carbonyls in LDL. Since lipid peroxidation did not 
occur under these experimental conditions, we proposed that reactive aldehydes in CSE 
directly modified certain amino residues of apolipoprotein B-100, specifically, free amino 
groups and free sulfhydryl groups. 
There is evidence that HDL also can be modified by cigarette smoke. It was first 
reported by Frei et al. [37] that the electrophoretic mobility of HDL on agarose gel was 
slightly increased after human plasma was treated with filtered gas phase cigarette smoke. 
Recent work by McCall et al. [40] confirmed this finding and further demonstrated 
crosslinking of HDL apolipoproteins by filtered gas-phase cigarette smoke. Although 
gas-phase cigarette smoke is known to induce lipid peroxidation in plasma, lipid 
peroxidation was not detected by TBARS assay in LDL and HDL isolated from cigarette 
smoke-treated plasma. Fatty acid analysis of LDL and HDL found little change upon 
exposure of plasma to cigarette smoke, further indicating lipid peroxidation was not 
involved in the modification of LDL and HDL. It was suggested by the researchers [40] 
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that reactive chemicals in cigarette smoke, particularly reactive aldehydes, directly 
modified HDL apolipoproteins. 
Inhibition ofLCAT Activity by Ci~arette Smoke and Reactive Aldehydes 
Cigarette smoke is rich in reactive aldehydes, including acetaldehyde, propanal, 
acrolein, crotonaldehyde, formaldehyde, and isovaleraldehyde [38]. Although no study 
has measured blood aldehyde levels in cigarette smokers, it is known that more than 90% 
of some hydrophilic volatile compounds, including acetaldehyde, is retained in human 
lungs during cigarette smoking [41]. Reactive aldehydes may react with different 
chemical groups on amino acid residues of proteins. In oxidative modification of LDL, 
reactive aldehydes generated from decomposition of lipid hydroperoxides covalently 
react with free amino groups on lysine residues to form Schiff s bases via nucleophilic 
addition [42]. Many a,~-unsaturated aldehydes, such as acrolein and crotonaldehyde in 
cigarette smoke, can also react with free amino groups or free sulfhydryl groups to form 
protein carbonyls via conjugated addition [43]. 
In a previous study [44], we found that CSE inhibited plasma LCAT activity. The 
decrease ofLCAT activity upon incubation of plasma with CSE was both time- and dose-
dependent. When different antioxidants were included in the incubation, only glutathione 
was effective in inhibiting the loss of LCAT activity caused by CSE. We proposed that 
glutathione protected LCAT from losing its activity by two possible mechanisms. First, 
glutathione preserves free sulfhydryl groups of LCAT. These free sulfhydryl groups 
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reside within the active site region of the enzyme and are required for LCAT activity 
[45]. Second, glutathione reacts with reactive chemicals in cigarette smoke, including 
aldehydes, and keep them from attacking free sulfhydryl groups ofLCAT. 
We further tested five reactive aldehydes, namely acrolein, hexanal, 
formaldehyde, malondialdehyde and acetaldehyde, for their effects on LCAT activity. All 
five aldehydes inhibited LCAT activity in a dose-dependent manner. Acrolein, the only 
a,~-unsaturated aldehyde tested, was 10 to 50 times more potent in inhibiting LCAT 
activity than the other reactive aldehydes. When included in the incubation, both 
glutathione and dihydrolipoic acid were each able to block the loss of LCAT activity 
caused by acrolein. 
Similar inhibition of LCAT activity with gas phase cigarette smoke and reactive 
aldehydes have been reported by McCall's group [46, 47]. Besides glutathione, they also 
showed that two other free sulfhydryl compounds, N-acetyl cysteine and 5,5' -dithiobis-
nitrobenzoic acid (DTNB), were able to block LCAT inhibition caused by cigarette 
smoke. 
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CHAPTER ill 
SPECIFIC AIMS AND RATIONALE 
Specific Aims 
Modification of human HDL by cigarette smoke may provide an explanation for 
the increased risk of atherosclerosis in cigarette smokers. To partially address this 
hypothesis, the mechanism by which CSE causes HDL modification and the impact of 
this modification on HDL function were investigated in this study. The specific aims are 
as follow: 
(1) to characterize modification of HDL by CSE with special emphasis on structural 
changes of apolipoproteins; 
(2) to determine if acrolein, the most potent reactive aldehyde known to be present in 
cigarette smoke, can directly modify HDL; 
(3) to examine whether CSE-mediated modification of HDL decreases the capacity of 
HDL to activate LCAT; 
(4) to determine whether CSE-modified HDL, as compared to native HDL, exhibits 
decreased capacity to stimulate cholesterol efllux from macrophages; 
(5) and, to evaluate the capacity of glutathione and aminoguanidine to prevent 
modification ofHDL and also any subsequent impairment ofHDL function. 
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Rationale 
Our previous study of LDL modification demonstrated that CSE possesses 
antioxidant activity and does not induce lipid peroxidation. We suggested that reactive 
aldehydes, instead of free radicals, in cigarette smoke might be responsible for LDL 
modification. Therefore, the initial study of the present project focused on structural 
modification of HDL lipoproteins by CSE and acrolein. SDS-PAGE was used in 
combination with Western-blot analysis to characterize structural modification of certain 
apolipoproteins, such as apolipoprotein A-1. Lysine residues of HDL apolipoproteins 
were analyzed because reactive aldehydes can form different adducts with free amino 
groups, particularly the E-amino group of lysine. Modification of HDL by acrolein was 
compared with modification of HDL by CSE to ascertain the possible role of reactive 
aldehydes in CSE-mediated HDL modification. 
The next study was to evaluate the impact of HDL modification on its biological 
function in reverse cholesterol transport. Since apolipoprotein A-I ofHDL is a cofactor of 
LCAT and might be modified by CSE, the capacity of HDL to activate LCAT was 
examined. Removal of intracellular cholesterol by HDL, another major function of HDL 
in reverse cholesterol transport, might be also decreased by CSE-mediated modification. 
In a third study, a cellular model was used to examine this possibility. 
There has been increasing interest in identifying compounds that can inhibit 
different types of lipoprotein modifications. Both glutathione and amino guanidine readily 
react with reactive aldehydes [43, 48]. Inclusion of these compounds in the incubation 
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should protect HDL from structural modification induced by acrolein. In addition, they 
might inhibit HDL modification by CSE if reactive aldehydes are indeed involved in the 
modification process. As such, these two possibilities were tested. Ascorbate, a classical 
antioxidant known to inhibit LDL oxidation, was also tested for its ability to inhibit CSE-
mediated HDL modification in certain experiments. Identification of compounds that 
. 
inhibit HDL modification could provide us with valuable information to understand 
mechanistically the basic biochemistry of HDL modification. More importantly, such 
compounds ·might be used as either dietary or medicinal agents to prevent HDL 
modification and, therefore, decrease the risk of atherosclerosis. 
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CHAPTER IV 
EXPERIMENTAL METHODOLOGY 
Chemicals 
[4-
14
C]-cholesterol (51.40 mCi or 1.9 Gbq/mmol) and e4C]-sodium acetate (57 
. 
mCilmmol) were purchased from New England Nuclear (Boston, MA). Acrolein and 
glutathione were obtained from Sigma Chemical Co. (St. Louis, MO). Aminoguanidine 
was obtained from Fisher Scientific Co. (Pittsburgh, PA). All other reagents were also 
obtained from either Fisher Scientific or Sigma Chemical Co. 
Isolation of HPL and Semi-purified LCAT Pre.paration from Plasma 
Blood samples were obtained from healthy, normolipidemic, adult male 
nonsmokers. Fasting blood was drawn by arm venipuncture using Vacutainer tubes with 
disodium ethylenediamine tetraacetic acid (EDT A) as anticoagulant. After centrifugation 
of the blood at 1,500 x g for 30 minutes at 4°C, plasma was recovered. Plasma density 
was raised to 1.21 g/ml with potassium bromide (0.3265 g/ml). Density-adjusted plasma 
was centrifuged at 114,000 x g for 40 hours at 4 oc in a Beckman L7-65 
ultracentrifuge/50.3 Ii rotor. The total lipoprotein fraction was then recovered from the 
top of each centrifuge tube. The clear zone in the middle of the tubes was also collected 
and used as a semi-purified LCAI source [28, 49] in LCAT activation experiments. HDL 
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in the total lipoprotein fraction was . separated from the other lipoprotein species by a 
density gradient procedure [50]. Briefly, 3.4 ml of the total lipoprotein fraction was 
overlaid with 8.5 m1 of a 0.9% sodium chloride solution containing 0.01% (w/v) EDTA 
(density= 1.006 glml) in Beckman 50 Ti rotor tubes. Tubes were centrifuged at 105,000 
x g for 4 hours at 18 °C. After recovery, the HDL was dialyzed against phosphate-
buffered saline (PBS) containing 1 mM EDTA, pH 7.4, at 4 oc for 24 hours. The semi-
purified LCAT preparation was dialyzed against LCAT assay buffer (10 mM Tris, 140 
mM NaCI and 1 mM EDT A, pH 7.4 [51]) at 4 oc for 20 hours. Protein concentrations of 
HDL and LCAT preparation were determined by the Bradford protein assay (Bio-Rad). 
After dialysis, aliquots of LCAT preparation were frozen at -20 .oc for later use in the 
LCAT activation experiments. 
Preparation ofCi~arette Smoke Extract (CSE) 
CSE was prepared using a procedure somewhat similar to that reported in another 
study [39]. Smoke from one burning University of Kentucky research cigarette (2Rl) was 
continuously bubbled through 1 m1 PBS, pH 7.4, at room temperature (Figure 2). The 
vacuum needed to "smoke" the cigarettes was supplied by a water-driven aspirator pump. 
It took about 2-3 minutes to consume one cigarette at a constant flow rate of 1.0 standard 
cubic foot per hour (SCFH), which was monitored with an air flow meter. PBS that was 
bubbled with plain air served as the control. Both preparations were individually 
\{! 
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filtered through 0.2 micron filters, and aliquots of the stock filtrates were immediately 
incubated with HDL as described below. 
ExPerimental Treatment of HPL 
HDL modification was induced by incubation of HDL (1 mg/ml) with different 
concentrations of either CSE (2.5-20%, v/v, volume of stock CSE comprising total 
incubation volume) or acrolein (0.1-0.8 mM) in the presence or absence of 
aminoguanidine or glutathione at 37 °C for 6 hours. When used in the subsequent LCAT 
activation and cholesterol eftlux experiments, the treated HDL samples were immediately 
dialyzed against the LCAT assay buffer or PBS (pH 7.4), respectively, at 4 °C. The 
dialysis buffer was changed twice over 20 hours. After dialysis, protein concentration of 
each HDL sample was determined as before. 
Determination ofReactive Amino Residues in HI)L Samples 
Levels of the free amino groups in apolipoproteins of HDL were determined with 
trinitrobenzenesulfonic acid (TNBS) using valine as a standard [52]. Briefly, 50 ~l of 
HDL sample was mixed with 1 ml of 4% NaC03, pH 8.4, and 50 ~l of 0.1 % TNBS. 
Samples were then incubated at 37 °C for 1 hour, and the absorbance at 340 nm was 
measured spectrophotometrically. 
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A~arose Gel Electrophoresis ofHDL Samples 
Electrophoretic mobility of HDL on agarose gel was evaluated by using a Ciba-
Corning complete electrophoresis system and pre-cast gels. More specifically, 2 J.ll of 
HDL sample was applied to each lane, and the gel was electrophoresed in the Universal 
Electrophoresis Cell base unit with the two chambers filled with 95 ml of Universal 
Buffer. After a 35 minute Iliil, the gel was dried in the dryer unit at 55°C. The gel was 
then incubated with Fat Red 7B staining solution for 5 minutes and destained in 
methanoVwater solution (5:2,v/v). The gel was dried again and photographed for a 
permanent record. 
SDS-PAGE ofHDL Samples 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-P AGE) of the 
HDL samples was performed under non-reducing conditions with a Mini-PROTEAN II 
electrophoresis system (Bio-Rad) using 4-20% Mini-PROTEAN gradient gels. HDL 
samples were diluted 1:1 (v/v) with sample buffer (a mixture of 4.4 ml of deionized 
water, 1.0 ml of 0.5 M Tris-HCl at pH 6.8, 0.8 ml of glycerol, 1.6 ml of 10% SDS, and 
0.2 m1 1% bromophenol blue). The diluted HDL samples were heated at 95°C for 5 
minutes. Then, 0.035 ml of each sample was loaded onto the gel. The gel was processed 
in the electrophoresis cell unit at a constant 200 volts for about 30 minutes to allow the 
tracking dye to migrate to 5 mm from the bottom of the gel. The gel was stained with a 
coomassie blue staining solution (2.5 g in 1 liter of methanol/acetic acid/water (4:1:5)) 
27 
for 30 minutes. Destaining of the gel was done using the same solvent system for the dye. 
The gel was then photographed for a permanent record. 
Western-blot of HDL Samples 
In some experiments, proteins in SDS-PAGE gels were Western-blotted to 
nitrocellulose membrane sheets with a Genie electrophoretic blotter (Idea Scientific Co.) 
following the manufacturer's instruction. The transfer was made in Tris-Glycine buffer 
(20% methanol), pH 8.3, at 24 volts for about 45 minutes. The nitrocellulose membrane 
was incubated with a blocking solution consisting of 3% gelatin in TBS (20 mM Tris, 
500 mM NaCl, pH 7.5) to block other protein-binding sites on the membrane. This step 
was performed on an orbital shaker at room temperature for an hour. Next, the membrane 
sheet was washed with a TTBS wash solution (20 mM Tris, 500 mM NaCl, 0.05% 
Tween-20, pH 7.5) for 10 minutes, again with gentle agitation at room temperature. 
The proteins on the nitrocellulose membranes were then immunodetected with 
murine monoclonal antibodies against human apolipoprotein A-1 and A-ll (Cappel) used 
in conjunction with an lmmun-Blot assay kit (Bio-Rad). The murine monoclonal 
antibody against human apolipoprotein A-I or A-ll was diluted by 1000-fold with an 
antibody buffer (1% gelatin in TfBS). The membrane sheet was incubated with 20 ml of 
the primary antibody solution overnight with gentle agitation. On the next morning, the 
membrane sheet was washed twice with TfBS for 5 minutes. The membrane sheet was 
then incubated with secondary antibody (goat anti-mouse IgG/alkaline phosphatase 
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conjugate) in 30 ml of antibody buffer for 2 hours. The membrane sheet was washed 
twice with ITBS. Just before color development, the membrane sheet was washed with 
TBS. Finally, the membrane sheet was incubated with 30 ml of color development 
solution supplied with the assay kit. The incubation was stopped by immersing the 
membrane sheet in deionized water for 10 minutes with gentle agitation with at least one 
change of water. The membrane sheet was air-dried and then photodocumented. 
Measurement ofHPL-mediated LCAI Activation 
Extent of LCAT activation by HDL was measured by a method derived from 
others [28, 51, 53, 54]. The albumin-stabilized [4-14C]-cholesterol was initially prepared 
according to Stokke and Narum [55]. Briefly, 5 J1Ci [4-14C]-cholesterol (51.40 
mCilmmol) was transferred into a small vial and the original solvent for the radiolabel 
was evaporated off by blowing with plain air. The "hot" residue was redissolved in 0.125 
ml of acetone. Using a Hamilton syringe, the radiolabelled cholesterol in acetone was 
added slowly, drop by drop, into 1.25 ml of 5% (w/v) albumin in 0.2 M phosphate buffer 
(pH 7.4) with continuous stirring. The vial was washed using additional acetone that was 
added to the albumin-containing solution to ensure quantitative transfer. The acetone was 
evaporated by carefully directing a stream of air over the albumin-containing solution. 
The LCAT activation assay was performed in an incubation mixture containing 25 
Jlg HDL, 10 Ill of semi-purified LCAT preparation (15 Jlg protein), 13 J.Ll of albumin-
stabilized [4_14C]-cholesterol (105 dpm), 5J.Ll of 0.1 M 13-mercaptoethanol, and LCAT 
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assay buffer to give a total incubation volume of I 00 fll. After 30 minut~s of incubation 
at 37 °C, the reaction was terminated by adding 2 m1 of chloroform-methanol (I:l, v/v). 
The samples were incubated overnight at room temperature to allow complete lipid 
extraction. 
The incubation mixture was filtered the next day through a I 0 cc plastic syringe 
barrel fitted with a fritted disc filter, and the precipitate was washed three times with 
chloroform/methanol. The combined filtrate was evaporated by directing a stream of 
plain air in a ventilation hood. The lipid residue was redissolved in 0.1 m1 chloroform, 
and 0.05 ml was applied to a previously activated TLC plate with a TLC Multi-Spotter 
(Alltech). The plate was developed in a TLC developing tank containing I86 ml of light 
petroleum (b.p. 40-60 °C) - diethyl ether- acetic acid , 85:I5:3 (v/v/v). Free cholesterol 
and cholesteryl esters were visualized on the plate by exposure to iodine vapor. The TLC 
gel bands containing free cholesterol and cholesteryl esters were scraped into 20 mlliquid 
scintillation vials using a razor-blade scraper. To each liquid scintillation vial, 10 ml of 
liquid scintillation cocktail (Scinti Verse ™ I from Fisher Scientific) was added. After 
thoroughly mixing, the samples were counted with a 2% counting error in a Beckman LS 
6000SE liquid scintillation system. 
This assay procedure excluded a preincubation period, normally to allow for 
equilibration between [4-14C]-cholesterol and endogenous HDL cholesterol, because 
uniform equilibration might not be possible among the different samples of HDL 
especially after modification. Therefore, extent of LCAT activation by HDL was 
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determined as amount of radioactivity in the cholesteryl ester fraction and expressed as 
percentage of control. The assay was linear for at least an hour. 
Assay of Cholesterol Efflux by HDL Samples 
The THP-1 human monocyte, a transformed monocytic leukemic cell, has been 
used in the study of lipoprotein-mediate cholesterol efflux previously [56]. THP-1 cells 
were cultured in RPMI-1640 medium, supplemented with 10% fetal calf serum (FCS), 10 
mM Hepes, 2 mM glutamine, 1 mM sodium pyruvate, 50 !lM 13-mercaptoethanol, 2.5 
units/ml penicillin, 2.5 units/ml streptomycin, and 0.5 J.Lg/ml fungizone. Cell culture was 
maintained in a humidified atmosphere of95% air, 5% C02 at 37 de. 
Efflux experiments were performed by modifying a published procedure [56]. 
Briefly, 3xl05 cells were seeded in each well of a 24-well culture dish with 1 m! of 
serum-free medium in which 10% FCS was replaced by 1% Nutridoma-HU (Boehringer 
Mannheim). Each well also received 5 J.LCi [14C]-sodium acetate (57 mCi/mmol). Non-
radioactive sodium acetate was added in the incubation to give a final concentration of 
0.5 mM acetate. Cells were incubated for 48 hours to allow incorporation of 14C-acetate 
into cholesterol and cholesteryl esters. Medium was removed at the end of the incubation 
and cells were washed twice with PBS, pH 7.4. Different cholesterol acceptors (0.1 
mglml), including control HDL and modified HDL, were then added for a further 24-hour 
incubation. Control cells received albumin instead of any lipoproteins. Native LDL and 
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oxidized HDL were used as negative and positive controls, respectively, in the 
experiments. Cells were then collected by centrifugation and washed with PBS, pH 7.4. 
Cellular cholesterol was extracted by incubating cell pellet with 1 ml of hexane-
isopropanol mixture (3:2, v/v) for one hour. The cell pellet was washed twice with 
hexane-isopropanol mixture, and the solvent was collected for cholesterol determination. 
The combined solvent was evaporated by directing a stream of air over the solvent 
surface in a ventilation hood. Cholesterol and cholesteryl esters were separated by thin-
layer chromatography using a two-solvent system. The TLC plate was placed in a TLC 
tank with first solvent, isopropyl ether-acetic acid (96:4), which was allowed to run to the 
middle of the plate. The plate was then dried and placed in another TLC tank with second 
solvent, hexane-diethyl ether-acetic acid (83:16:1), for complete development. The TLC 
bands containing free cholesterol and cholesteryl esters were identified and their 
radioactivities were determined with a Beckman LS 6000SE scintillation spectrometer. 
After lipid extraction, each cell pellet was incubated with 0.2 N NaOH for an hour 
and cellular protein was determined as above. The cellular cholesterol was calculated and 
expressed as DPM/J.Lg protein. 
Statistical Analysis of Experimental Data 
All experiments were performed in at least triplicate and repeated three times 
unless otherwise stated. Since multiple incubations were conducted, one-way analysis of 
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variance (ANOVA) followed by Duncan's multiple range test was performed using SAS 
program to analyze data for significant differences (P,O.OS). 
CHAPTERV 
RESULTS 
Relative Level~ of Reactive Amino Groups in HPL Samples 
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When incubated with HDL for 6 hours, CSE, in a concentration-dependent 
manner, decreased HDL reactive amino groups relative to control HDL which contained 
1.3 nmol reactive amino groups per mg of protein (Table I). At 2.5% (v/v), CSE caused a 
6% decrease in HDL reactive amino groups. \\'hen the concentrations of CSE was 
increased to 5%, 10% and 20%, reactive amino groups in HDL decreased 14%, 24% and 
33%, respectively. The effect of acrolein on HDL reactive amino groups followed the 
same pattern (Table I). When HDL was incubated with 0.1, 0.2, 0.4 and 0.8 mM a~rolein, 
HDL reactive amino groups decreased by 6%, 12%,28% and 33%, respectively. 
Aaarose Gel Electrophoresis ofHPL Samples 
As shown in Figure 3, HDL samples that were incubated with increasing 
concentrations of either CSE (lanes 2-5) or acrolein (lanes 8-11) progressively migrated 
further to the anode than the respective control HDL samples (lane 1 and lane 7). 
Although the increases in electrophoretic mobility of HDL caused by CSE or acrolein 
appeared to be relatively small, they were reproducible and concentration-dependent. 
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Table I. Relative levels of reactive amino groups in HDL samples after incubation with 
either CSE or acrolein. 
Sample 
ControlHDL 
HDL/2.5% CSE 
HDL/5%CSE 
HDL/10%CSE 
HDL/20%CSE 
Control HDL 
HDL/0.1 mM acrolein 
HDL/0.2 mM acrolein 
HDL/0.4 mM acrolein 
HDL/0.8 mM acrolein 
Reactive amino group (%) 
1QQ±3A 
94±28 
86±3c 
76±4° 
67±3E 
100±33 
94±1b 
88±lc: 
72±2d 
67±2e 
HDL (1 mglml) was incubated for 6 hours at 37 oc with· increasing concentrations of 
either CSE or acrolein in a total incubation volume of 100 1-11. After incubation, levels of 
free amino groups in 50 1-11 of HDL samples were determined. Results are the 
mean±S.E.M. of triplicate incubations using the same CSE preparation. Superscipts 
represent Duncan groupings. The experiment was repeated three times. Level of free 
amino groups iri control HDL was 1.3 nmollmg protein. 
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Figure 3. Agarose gel electrophoretic mobility of HDL incubated with different 
concentrations of either CSE or acrolein. HDL (I mg/ml) was incubated with increasing 
concentrations of either CSE or acrolein at 3 7 °C for 6 hours. After incubation, samples 
were subj~cted to agarose gel electrophoresis and then stained. The arrow indicates the 
well position for sample application. The samples in the gel lanes are as follow: lane I, 
control HDL; lane 2, HDL incubated with 2.5% CSE; lane 3, HDL incubated with 5% 
CSE; lane 4, HDL incubated with IO% CSE; lane 5, HDL incubated with 20% CSE; lane 
6, no sample applied; lane 7, control HDL; lane 8, HDL incubated with 0.1 mM acrolein; 
lane 9, HDL incubated with 0.2 mM acrolein; lane IO, HDL incubated with 0.4 mM 
acrolein; lane II, HDL incubated with 0.8 mM acrolein; lane I2, no sample applied. The 
gel is a representation of three separate experiments. 
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In other agarose gel electrophoretic experiments, we examined the protective 
effects of aminoguanidine and glutathione against HDL modification caused by CSE and 
acrolein. Aminoguanidine at concentrations of 5, 25 or 50 mM and glutathione at 
concentrations of 1, 5 or 10 mM were tested. After HDL was incubated with either 20% 
(v/v) CSE or 0.8 mM acrolein in the absence or presence of either am.inoguanidine or 
glutathione, the relative electrophoretic mobility (REM) was calculated for each HDL 
sample. The results are sho\vn in Table IT. Incubation of HDL with either CSE or acrolein 
increased the REM values of HDL from 1.0 to 1.2 and 1.3, respectively. At the tested 
concentrations, both aminoguanidine (5.0 mM) and glutathione (LO mM) were very 
effective in preventing the increase of electrophoretic mobility of HDL caused by 
acrolein. Glutathione at 1 mM also completely inhibited the increase of electrophoretic 
mobility of HDL caused by CSE. Aminoguanidine at 5 mM did not have any inhibitory 
effect on the increase of electrophoretic mobility of HDL caused by CSE. When its 
concentrations was increased to 25 mM, aminoguanidine decreased REM of CSE-treated 
HDL to 1.1. At the highest concentration (50 mM), aminoguanidine completely inhibited 
the increase of electrophoretic mobility ofHDL caused by CSE. 
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Table IT. Relative electrophoretic mobility (REM) of HDL incubated with either CSE or 
acrolein in the presence or absence of amino guanidine (AG) or glutathione (GSH). 
Sample 
ControlHDL 
HDLISOmMAG 
HDLII 0 mM GSH 
.HDL/20%CSE 
.HDL/20% CSE/5.0 mM AG 
.HDL/20% CSE/25 mM AG 
.HDL/20% CSE/50 mM AG 
.HDL/20% CSEII.O mM GSH 
.HDL/0.8 mM acrolein 
.HDL/0.8 mM acrolein/5.0 mM AG 
.HDL/0.8 mM acrolein/I.O mM GSH 
REM 
1.0· 
1.0 
1.0 
1.2 
1.2 
1.1 
1.0 
1.0 
1.3 
1.0 
1.0 
HDL (I mg/ml) was incubated with either 20% (v/v) CSE or 0.8 mM acrolein in the 
presence or absence of different concentrations of amino guanidine or glutathione at 3 7 oc 
for 6 hours. After incubation, HDL samples were subjected to I% agarose gel 
electrophoresis. REM was calculated as the ratio of migration distance (from the gel well 
origin) of treated HDL to that of control HDL. The results are a representation of three 
separate experiments. 
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SDS-PAGE and Western-Blot ofHPL Samples 
As presented in Figures 4 and 5, results of SDS-PAGE show that apolipoproteins 
are modified after incubation of HDL with CSE (Figure 4) or acrolein (Figure 5). 
Apolipoproteins A-I and A-II were the major proteins in control HDL after SDS-P AGE 
(Lane 1 in both Figures). Incubation of HDL with 20% CSE (Figure 4, Lane 2) or 0.8 
mM acrolein (Figure 5, Lane 2) resulted in apolipoprotein crosslinking as indicated by 
the presence of multiple high molecular weight bands in both of the gel lanes. Moreover, 
the intensity of both apolipoprotein A-I and A-II bands was noticeably decreased by CSE 
and acrolein. After apolipoproteins on duplicate gels were Western-blotted to 
nitrocellulose membranes, all high molecular weight bands cross-reacted with both a 
murine monoclonal antibody against apolipoprotein A-I (Figure 6, Membrane I) and a 
murine monoclonal antibody against apolipoprotein A-II (Figure 6, Membrane II). · 
As further seen on the gels, aminoguanidine (Figure 5, Lanes 3-5) and glutathione 
(Figure 5, Lanes 6-8) inhibited acrolein-induced apolipoprotein crosslinking in a 
concentration-dependent manner. At the highest concentrations used, amino guanidine (50 
mM, Lane 5) and glutathione (1 0 mM, Lane 8) almost completely protected 
apolipoproteins from crosslinking caused by acrolein. Glutathione also reduced 
apolipoprotein A-II dimer (D) to monomeric form (M). To a lesser extent, glutathione 
also inhibited CSE-induced apolipoprotein crosslinking in a concentration-dependent 
manner (Figure 4, Lanes 6-8). The protective effect of aminoguanidine on CSE-induced 
apolipoprotein crosslinking was minimal (Figure 4, Lanes 3-5). 
Lanes 
CSE (l0°/o) 
AG(mM) 
GSH(mM) 
ApoA-1 ~ 
Apo A-ll (D) -+ 
Apo A-ll (M) -+ 
1 l 34 s 6 7 8 
+ ++ + + + + 
5 25 SO-
5 10 
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Figure 4. SDS-P AGE of HDL after incubation with CSE in the presence or absence of 
aminoguanidine (AG) or glutathione (GSH). HDL (1 mg/ml) was incubated with 20% 
CSE in the presence or absence of different concentrations of either aminoguanidine or 
glutathione at 37 oc for 6 hours. After incubation, samples containing equal amounts of 
protein were subjected to SDS-PAGE and then stained. The gel is a representation of 
three separate experiments. 
Lanes 
Acrolein (0.8mM) 
AG(mM) 
GSH(mM) 
ApoA-1 ~ 
ApoA-ll(D) ~ 
ApoA-ll(M)~ 
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12 3 4 s 6 78 
+ + + + + ++ 
5 25 50 -
5 10 
Figure 5. SDS-PAGE ofHDL after incubation with acrolein in the presence or absence of 
aminoguanidine (AG) or glutathione (GSH). HDL (1 mg/ml) was incubated with 0.8 mM 
acrolein in the presence or absence of different concentrations of either aminoguanidine 
or glutathione at 37 °C for 6 hours. After incubation, samples containing equal amounts 
of protein were subjected to SDS-PAGE and then stained. The gel is a representation of 
three separate experiments. 
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Figure 6. Western-blots of HDL samples after SDS-PAGE. HDL (1 mglml) was 
incubated with either 20% CSE or 0.8 mM acrolein at 3 7 oc for 6 hours. After 
incubation, samples containing ectual amounts of protein were subjected to SDS-P AGE. 
Proteins were then Western-blotted to nitrocellulose membranes and probed with either a 
murine monoclonal antibody against apolipoprotein A-1 (Membrane I) or a murine 
monoclonal antibody against apolipoprotein A-II (Membrane II). The samples on both 
nitrocellulose membranes are as follow: Lane 3, control HDL; Lane 2, HDL incubated 
with 20% CSE; Lane 1, HDL incubated with 0.8 mM acrolein. 
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LCAI Activation Capacity by HDL Samples 
Modification of HDL by either CSE or acrolein caused a statistically significant 
decrease· in HDL's capacity to activate LCAT. This reduction in LCAT activation 
capacity caused by CSE or acrolein was both time-dependent (Figure 7) and 
concentration-dependent (Figures 8 and 9). As shown in Figure 7, incubation of HDL 
with 20% CSE for 0.5 hour resulted in a sharp 21% decrease in LCAT activation capacity 
of HDL. As incubation time increased from 0.5 to 6 hours, there was a progressive 
decrease in HDL's capacity to activate LCAT. However, the rate of decline in LCAT 
activation capacity of HDL was not as sharp, especially up to 4 hours. After incubation 
with CSE for 6 hours, HDL lost 48% of its capacity to activate LCAT. Incubation of 
HDL with 0.8 mM of acrolein also caused a sharp decrease (24%) in LCAT activation 
capacity at 0.5 hour (Figure 7). This trend continued for 2 hours, with 33% and 53% 
decrease of LCA T activation capacity at the end of 1 and 2 hours of incubation, 
respectively. However, during the next 4 hours, there was only 10% additional decrease 
ofLCAT activation capacity ofHDL. As shown in Figure 8, HDL was also sensitive to 
low concentrations of CSE with respect to being modified and losing some of its capacity 
to activate LCAT. After incubation with 2.5% CSE for 6 hours, HDL lost 21% of its 
capacity to activate LCAT. The loss of LCAT activation capacity of HDL increased as 
HDL was incubated with increasing CSE concentrations. The decreases of LCA T 
activation capacity were 33%,39% and 59% after HDL was incubated with 5%, 10% and 
20% CSE, respectively, for 6 hours. Acrolein from 0.1 to 0.8 mM produced similar 
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Figure 7. Loss ofLCAT activation capacity ofHDL after incubation ofHDL with either 
CSE or acrolein. HDL (1 mg/ml) was incubated with either 20% CSE or 0.8 mM acrolein 
for different time periods up to 6 hours. LCAT activation capacity of treated HDL was 
then determined. The assay mixture in a total incubation volume of 1 00 f.d contained 25 
J.Lg of treated HDL, 10 J.Ll ofLCAT enzyme preparation (15 J.Lg protein), 13 J.Ll of albumin-
stabilized [4-14C]-cholesterol (105 dpm), and 5J.Ll of 0.1 M ~-mercaptoethanol. After 30 
minutes of incubation at 37 °C, the reaction was terminated by adding 20 volumes of 
chloroform-methanol (1: 1,v/v). Following lipid extraction and then separation of 
cholesteryl ester from unesterified cholesterol by thin-layer chromatography, 
radioactivity in the TLC fractions was measured by liquid scintillation spectrometry. 
LCAT activation capacity was determined as amount of radioactivity detected in the 
cholesteryl ester fraction and expressed as percentage of control. The values are the 
means of triplicate incubations using the same batch of CSE. The experiment was 
repeated three times. 
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Figure 8. Loss of LCAT activation capacity of HDL after incubation of HDL with 
different concentrations of CSE. HDL (1 mg/ml) was incubated with different 
concentrations of CSE for 6 hours. LCAT activation capacity of treated HDL was then 
determined. The assay mixture in a total incubation volume of 100 J.ll contained 25 J.lg of 
treated HDL, 10 Ill of LCAT enzyme preparation (15 J.lg protein), 13 J.ll of albumin-
stabilized [4-14C]-cholesterol (105 dpm), and 5!ll of 0.1 M ~-mercaptoethanol. After 30 
minutes of incubation at 37 °C, the reaction was terminated by adding 20 volumes of 
chloroform-methanol (1:1,v/v). Following lipid extraction and then separation of 
cholesteryl ester from unesterified cholesterol by thin-layer chromatography, 
radioactivity in the TLC fractions was measured by liquid scintillation spectrometry. 
LCA T activation capacity was determined as amount of radioactivity detected in the 
cholesteryl ester fraction and expressed as percentage of control. The values are the 
means of triplicate incubations using the same batch of CSE. The experiment was 
repeated three times. 
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reduction of LCAT activation capacity of HDL with 6 hours of incubation (Figure 9). 
Inhibition of LCAT activation capacity increased from 31% with 0.1 mM acrolein to 
39%, 48%, and 63% as acrolein concentrations increased to 0.2, 0.4 and 0.8 mM, 
respectively. 
In accord with results from the previous experiments, both aminoguanidine 
(Figure 1 0) and glutathione (Figure 11) prevented loss of LCA T activation capacity of 
HDL caused by acrolein. When 5 mM aminoguanidine was present as HDL incubated 
with 0.8 mM acrolein, 89% ofHDL's capacity to activate LCAT remained in comparison 
to 34% LCAT activation capacity of HDL incubated with acrolein in the absence of 
amino guanidine (Figure I 0). It required a much higher concentration of amino guanidine 
(50 mM) to totally prevent the loss of LCAT activation capacity of HDL caused by 
acrolein. Glutathione at 1 mM provided a similar degree of protection as 5 mM 
aminoguanidine against acrolein-induced loss of LCAT activation capacity of HDL 
(Figure 11 ). A higher concentration of glutathione (5 mM) completely prevented the loss 
ofLCAT activation capacity ofHDL caused by acrolein. 
Aminoguanidine and glutathione inhibited the loss of LCAT activation capacity 
of HDL caused by CSE as well (Figures 10 and 11). However, the inhibitory effect of 
both compounds was less pronounced in comparison to that of acrolein-induced loss of 
LCAT activation capacity of HDL. Presence of 5, 25 and 50 mM aminoguanidine as 
HDL was incubated with CSE resulted in an increase in LCAT activation capacity from 
41% to 50%, 56% and 62%, respectively. Similarly, with 1, 5 and 10 mM glutathione, 
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Figure 9. Loss of LCAT activation capacity of HDL after incubation of HDL with 
different concentrations of acrolein. HDL (1 mg/ml) was incubated with different 
concentrations of acrolein for 6 hours. LCAT activation capacity of treated HDL was then 
determined. The assay mixture in a total incubation volume of 100 J.Ll contained 25 J.Lg of 
treated HDL, 10 J.Ll of LCAT enzyme preparation (15 J.Lg protein), 13 J.Ll of albumin-
stabilized [4-14C]-cholesterol (105 dpm), and 5J.Ll of 0.1 M ~-mercaptoethanol. After 30 
minutes of incubation at 37 °C, the reaction was terminated by adding 20 volumes of 
chloroform-methanol (l:l,v/v). Following lipid extraction and then separation of 
cholesteryl ester from unesterified cholesterol by thin-layer chromatography, 
radioactivity in the TLC fractions was measured by liquid scintillation spectrometry. 
LCA T activation capacity was determined as amount of radioactivity detected in the 
cholesteryl ester fraction and expressed as percentage of control. The values are the 
means of triplicate incubations using same batch of CSE. The experiment was repeated 
three times. 
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Figure 10. Effects of aminoguanidine on loss of LCAT activation capacity of HDL 
caused by either CSE and acrolein. HDL (1 mg/ml) was incubated for 6 hours with either 
0.8 mM acrolein or 20% CSE in the absence or presence of aminoguanidine. LCA T 
activation capacity of treated HDL was then determined. The assay mixture in a total 
incubation volume of 100 J.Ll contained 25 J.Lg of treated HDL, 10 J.L1 of LCAT enzyme 
preparation (15 J.Lg protein), 13 J.Ll of albumin-stabilized [4.l4C]-cholesterol (105 dpm), 
and 5J.Ll of 0.1 M ~-mercaptoethanol. After 30 minutes of incubation at 37 °C, the 
reaction was terminated by adding 20 volumes of chloroform-methanol (l:l,v/v). 
Following lipid extraction and then separation of cholesteryl ester from unesterified 
cholesterol by thin-layer chromatography, radioactivity in the TLC fractions was 
measured by liquid scintillation spectrometry. LCAT activation capacity was determined 
as amount of radioactivity detected in the cholesteryl ester fraction and expressed as 
percentage of control. The values are the means of triplicate incubations using the same 
batch of CSE. The experiment was repeated three times. 
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Figure 11. Effects of glutathione on Loss ofLCAT activation capacity ofHDL caused by 
either CSE and acrolein. HDL (1 mg/ml) was incubated for 6 hours with either 0.8 mM 
acrolein or 20% CSE in the absence or presence of glutathione. LCA T activation capacity 
of treated HDL was then determined. The assay mixture in a total incubation volume of 
100 J,Ll contained 25 J.Lg of treated HDL, 10 J,Ll of LCAT enzyme preparation (15 J,Lg 
protein), 13 J.Ll of albumin-stabilized (4-14C]-cholesterol (105 dpm), and 5J.Ll of 0.1 M P-
mercaptoethanol. After 30 minutes of incubation at 37 °C, the reaction was terminated by 
adding 20 volumes of chloroform-methanol (l:l,v/v). Following lipid extraction and then 
separation of cholesteryl ester from unesterified cholesterol by thin-layer 
chromatography, radioactivity in the nc fractions was measured by liquid scintillation 
spectrometry. LCAT activation capacity was determined as amount of radioactivity 
detected in the cholesteryl ester fraction and expressed as percentage of control. The 
values are the means of triplicate incubations using the same batch of CSE. The 
experiment was repeated three times. 
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LCAT activation capacity of HDL increased from 36% to 41%, 45% and 65%, 
respectively. LCAT activation capacity was not affected when HDL was incubated with 
either aminoguanidine or glutathione alone at any tested concentration (data not shown). 
Cellular Cholesterol Efflux by HDL samples 
After THP-1 cells were incubated with e4C]-sodium acetate for 48 hours and 
treated with PBS for another 24 hours, the radioactivity associated with total cellular 
cholesterol was 884±33 DPM11-1g protein. Cellular e4C]-cholesteryl esters and e4C]-free 
cholesterol were 178±14 DPM11-1g protein and 706±19 DPM11-1g protein. respectively 
(Figure 12). Incubation ofTHP-1 cells with bovine serum albumin (BSA, 0.1 mg/ml) in 
PBS caused a slight decrease in both cellular [14C]-cholesteryl esters and e4C]-free 
cholesterol to 133±15 DPM11-1g and 669±37 DPM/J.Lg protein, respectively. The total 
cellular [14C]-cholesterol was 802±45 DPM11-1g protein. In comparison to the BSA 
control, LDL (0.1 mglml)caused little change in total cellular [14C]-cholestero1 (773±28 
DPM11-1g protein). However, cellular e4C]-cholesteryl esters increased to 282±13 
DPM11-1g protein and cellular e4C]-free cholesterol decreased to 491±26 DPM/J.Lg protein. 
THP-1 cells incubated with control HDL (0.1 mg/ml) had significantly less total 
cellular e4C]-cholesterol than cells incubated with BSA. HDL caused a 25% decrease in 
cellular e4C]-cholesteryl esters (from 133±15 to 102±1 DPM11-1g protein) and a 14% 
decrease in cellular e4C]-free cholesterol (from 669±37 to 572±22 DPMIJ.Lg protein), 
resulting in a 16% decrease in total cellular e4c]-cholesterol (from 802±45 to 674±23 
DPM11-1g protein). After incubation with 20% CSE for 6 hours, HDL did not lose any of 
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Table III. Cellular e4C]-cholesterol after incubatiop of THP-1 cells with various 
experimental components. 
Treatment 
PBS 
BSA 
LDL 
HDL 
HDLICSE 
HDLI Acrolein 
HDL/Copper 
CE 
178±13.7b 
133±14.7cd 
282±13.0a 
102±0.83e 
107±8.55dc 
112±2.66dc 
155±11.4bc 
FC 
(DPM/~g protein) 
706±19.2a 
669±37.0ab 
491±25.5d 
572±22.1cd 
591±19.9bc 
582±16.9bc 
623±41.0abc 
TC 
884±32.9a 
802±44.9ab 
773±27 .5bcd 
674±22.7d 
698±24.8cd 
694±17.0cd 
778±36.7bc 
HDL (1 mg/ml) was incubated with either 20% CSE, 0.8 mM acrolein, or 10 ~M cupric 
chloride at 37 oc for 6 hours. TifP-1 cells were cultured as described in the 
"Experimental Methodology") and exposed to the various experimental components for 
24 hours. Cellular total e4C]-cholesterol (TC) was determined by liquid scintillation 
spectrometry following separation of free cholesterol (FC) and cholesteryl esters (CE). 
The values are the means ± SEM of triplicate cultures. The experiment was repeated three 
times. Superscripts represent Duncan groupings. Means with the same letter in the 
column are not statistically significantly different (P<O.OS). 
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its capacity to promote cholesterol efflux. THP-1 cells incubated with CSE-treated HDL 
(0.1 mglml) had 107±9 DPM/J.Lg protein rt4C]-cholesteryl esters, 591±20 DPM/J.Lg 
protein [14C]-free cholesterol and 698±25 DPM/J.Lg protein total cellular e4C]-cholesterol. 
These values are comparable to those in 111P-I cells treated with control HDL. 
Incubation of I:IDL with 0.8 mM acrolein for 6 hours also did not have any effect on 
HDL's capacity to promote cholesterol efflux. THP-1 cells incubated with acrolein-
treated HDL (0.1 mglml) had 112±3 DPM/J.lg protein C4CJ-cholesteryl esters, 582±17 
DPM/J.lg [14C]-free cholesterol, and 694±17 DPM/J.lg total cellular [14C]-cholesterol. On 
the other hand, HDL oxidized with 10 J.LM copper for 6 hours lost some of its capacity to 
promote cholesterol effiux from THP-1 cells. Compared to BSA treatment, THP-1 cells 
incubated with copper-treated HDL (0.1 mglml) did not show any decrease in cellular 
cholesterol with [14C]-cholesteryl esters, [14C]-free cholesterol and total [14C]-cholesterol 
being 155±11, 623±41 and 778±37 DPM/J.lg protein, respectively. 
CHAPTER VI 
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Epidemiological data indicate that there is an inverse relationship between blood 
HDL levels and incidence of atherosclerosis [4]. The antiatherogenic effect of HDL has 
been attributed to its important function in reverse cholesterol transport [2]. Therefore, it 
is conceivable that modification of HDL may impair reverse cholesterol transport and 
increase risk of atherosclerosis. 
HDL can be oxidized in vitro by exposure to different oxidative agents including 
copper, AAPH and ionizing radiation. During HDL oxidation, lipid peroxidation occurs 
and results in the formation of fatty acid epoxides, oxidized cholesterol derivatives and 
lysophophatidylcholine [57]. Lipid peroxidation can be detected by noting the formation 
of conjugated diene followed by TSARS [27]. Similar to oxidized LDL, oxidized HDL 
has decreased lysine amino groups coincident with increased agarose gel electrophoretic 
mobility. Unlike LDL oxidation, HDL oxidation causes apolipoprotein crosslinking 
instead of apolipoprotein fragmentation. Several studies [25-28] have found that after 
HDL is oxidatively modified by copper, it loses its capacity to activate LCAT and to 
stimulate cholesterol effiux. 
In the present study, HDL incubated with CSE also had decreased reactive amino 
groups, increased agarose gel electrophoretic mobility, and crosslinked apolipoproteins. 
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However, it seems that CSE modifies HDL in a non-oxidative manner based on previous 
work demonstrating that CSE has antioxidant activity by virtue of its ability to inhibit 
LDL oxidation [39]. Furthermore_, ascorbate from 0.1 to 10 mM was not able to inhibit 
modification of HDL by CSE (data not shown). In another study, plasma HDL modified 
by gas-phase cigarette smoke shared similar physicochemical properties, including 
increased electrophoretic mobility and apolipoprotein crosslinking [40]. Also, lipid 
peroxidation was not detected by measuring TBARS and fatty acid composition in HDL. 
Therefore, modification of HDL by cigarette smoke does not appear to be mediated by 
any free radicals. 
The most important finding of the present study is that HDL lost a significant 
extent of its capacity to activate LCAT after modification by CSE. The LCAT activation 
capacity of HDL was very sensitive to the CSE treatment. After incubation with a low 
concentration of2.5% CSE for 6 hours, HDL lost 21% of its capacity to activate LCAT. 
Incubation of HDL with 20% CSE for half an hour decreased its capacity to activate 
LCAT by 24%. In another study by the author [44], it was demonstrated that LCAT 
activity decreased rapidly upon incubation of plasma with CSE. It is possible that 
modification ofHDL in the plasma by CSE also contributed to the loss ofLCAT activity 
observed in that study [44]. Since LCAT activity per se was not decreased in cigarette 
smokers as reported in several studies [58-60], this new finding concerning an effect of 
CSE on HDL, as opposed to an effect of CSE on LCAT, provides the rationale to further 
examine possible impairment ofLCAT function in cigarette smokers. 
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It is apparent that other chemical species in CSE caused non-oxidative 
modification of HDL. Cigarette smoke contains many reactive aldehydes [38]. Reactive 
aldehydes can react covalently with free amino groups, such as £-amino groups of lysine, 
via nucleophilic addition to form Schiff's base products [43]. Lysine and arginine 
residues make up a significant portion of the amino acid composition of apolipoprotein 
A-I [61]. Reaction of reactive aldehydes in CSE with free amino groups of lysine and 
arginine in apolipoprotein A-1 could reduce overall positive charge on this protein, which 
would lead to increased electrophoretic mobility of HDL on agarose gel. It has been 
suggested that positive charges on the lysine and arginine residues of apolipoprotein A-I 
are important for LCAT activation [62]. Reactive aldehydes can also cause apolipoprotein 
crosslinking in HDL [28, 46]. 
To provide support to the hypothesis that reactive aldehydes are involved in the 
modification of HDL by CSE, we compared CSE with acrolein, a major reactive 
aldehyde in cigarette smoke, in terms of their abilities to modify HDL. Acrolein and CSE 
had similar effects on HDL. Both CSE and acrolein caused a decrease in free amino 
groups, increase in electrophoretic mobility, and apolipoprotein crosslinking. In addition, 
both CSE and acrolein modified HDL in such a way as to cause HDL to have decreased 
capacity to activate LCAT. Thus, the data indicate that acrolein and CSE modified HDL 
in a similar manner, resulting in loss of apolipoprotein A-1-dependent LCAT activation 
capacity ofHDL. 
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Although reactive aldehydes are apparently implicated, other chemical 
components in cigarette smoke may also be involved in the modification ofHDL by CSE. 
This possibility is supported by other experiments we performed. More specifically, 
aminoguanidine and glutathione were tested to determine if either compound could 
inhibit HDL modification caused by CSE and acrolein. Both aminoguanidine and 
glutathione are very reactive toward aldehydes that can modify protein amino groups [43, 
48]. It has been shown that aminoguanidine can prevent protein crosslinking initiated by 
glycosylation in diabetes [63]. Glutathione can inhibit loss of LCAT activity in human 
plasma exposed to either cigarette smoke or CSE [40, 44, 47]. Thus, the presence of 
amino guanidine and glutathione during incubation of HDL with CSE should protect free 
amino groups of HDL from attack by reactive aldehydes. As expected, both 
aminoguanidine and glutathione were able to exert this effect and thus completely 
prevented HDL modification and subsequent loss of LCAT activation capacity of HDL 
caused by acrolein. However, when tested against CSE-mediated HDL modification, both 
aminoguanidine and glutathione completely prevented only the increase in 
electrophoretic mobility but not apolipoprotein crosslinking of HDL. The inhibitory 
effects of aminoguanidine and glutathione on loss of LCAT activation capacity of HDL 
caused by CSE were also incomplete. Hence, other class(es) of chemicals in CSE besides 
reactive aldehydes remains to be examined for capacity to modify HDL and cause loss of 
LCAT activation capacity ofHDL. 
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Structural characterization of apolipoprotein crosslinking of HDL after incubation 
with CSE has not been attempted. Besides lysine and arginine, other amino acids of 
apolipoproteins might be affected by cigarette smoke components. Cigarette smoke is 
able to modify tyrosine and generate a dimeric product referred to as dityrosine [64]. The 
modification of tyrosine by cigarette smoke is thought to be mediated by nitrogen 
compounds, such as NO and N02• This type of modification was partially inhibited by 
certain antioxidants, including glutathione, ascorbic acid and uric acid. In our work, it is 
possible that tyrosine residues of HDL apolipoproteins were modified and crosslinked by 
CSE which might contain NOIN02 [65]. The importance of tyrosine residues in LCAT 
activation by apolipoprotein A-1 is not known. On the other hand, modification of HDL 
by copper and malondialdehyde decreases tryptophan residues, in addition to free amino 
groups, of HDL apolipoproteins, and the modified HDL had decreased capa;:ity to 
activate LCAT [28]. 
Although apolipoproteins are modified when HDL is incubated with CSE, 
phospholipids of HDL could possibly be modified also in a manner not involving lipid 
peroxidation. Phosphatidylethanolamine (PE) contains a free amino group that can react 
with glucose-derived carbonyls to form Schiff's base products [66]. Therefore, PE of 
HDL might react with reactive aldehydes in CSE as well. Since PE is implicated in the 
binding of LCAT to HDL [67], CSE-induced modification of PE could limit availability 
of HDL substrate to LCAT enzyme molecules. In addition, two other studies [68, 69] 
have found that PE and also phosphatidylserine can crosslink with apolipoproteins when 
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HDL is incubated with either dimethylsuberimidate (DMS) or tetranitromethane (TMN). 
However, it is not known if these compounds are present in cigarette smoke. 
Nevertheless, it is possible that reactive chemicals in cigarette smoke, including reactive 
aldehydes, may also cause crosslinking of apolipoproteins to phospholipids in HDL. 
Although CSE-mediated modification decreased HDL 's capacity to activate 
LCAT, it did not change HDL 's capacity to promote cholesterol efflux from THP-1 cells. 
In contrast, HDL oxidized by copper showed a decreased capacity to mediate cholesterol 
efflux. The phenomenon of HDL-mediated cholesterol efflux has been studied for more 
than a decade and the mechanism is still under debate. Cholesterol efflux may be 
mediated by either HDL lipids or HDL apolipoproteins or both. In the diffusion-based 
efflux model, HDL phospholipid content and its ratios to HDL apolipoproteins and 
cholesterol determine the efficiency of cholesterol removal. In the receptor-dependent 
efflux model, the binding of HDL to its receptor on cell surface trigger the release of 
intracellular cholesterol to HDL particles. 
Based on the data in the current study, it might be concluded that CSE did not 
affect HDL to cause either lipid/protein ratio changes or loss of binding affinity to HDL 
receptors. Oxidation modifies both lipid and protein moieties of HDL particles. Oxidized 
HDL also has reduced ligand binding activity to macrophages [26]. It is very difficult to 
differentiate the effects of lipid and protein oxidation on HDL-mediated cholesterol 
efflux. However, Morel [70] demonstrated that cholesterol effiux capacity of HDL 
decreased before HDL apolipoprotein crosslinking occurred under mild oxidation 
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conditions with copper. There were only a decrease in total phospholipids and an increase 
in TBARS. Agarose gel electrophoretic mobility also did not change. Rifici eta!. [27] 
further demonstrated a negative linear correlation (r = -0.97) between cholesterol efflux 
and TBARS formation in oxidized HDL. Since lipid-free apolipoproteins are known to 
promote cholesterol efflux [71 ], they isolated apolipoproteins from oxidized HDL and 
compared its capacity to promote cholesterol efflux with apolipoproteins isolated from 
control HDL. The oxidized apolipoproteins had similar effect on cholesterol efflux as the 
control apolipoproteins. Therefore, HDL lost its capacity to stimulate cholesterol efflux 
because of lipid oxidation but not protein oxidation. In the present work, CSE-modified 
HDL did not seem to have elevated levels ofTBARS and did not have reduced capacity 
to stimulate cholesterol efflux. 
Some studies demonstrated that an HDL binding protein increased after cells were 
enriched with cholesterol [10, 11, 26]. This seems to suggest that an HDL receptor 
facilitates cholesterol removal from the cells. One study [26] found that crosslinking of 
HDL apolipoproteins by TNM caused a parallel decrease of HDL binding activity to 
macrophages and HDL-mediated cholesterol efflux from the macrophages. However, 
1NM also induces lipid peroxidation of HDL which may contribute to the decrease in 
cholesterol efllux. On the other hand, DMS also caused crosslinking of HDL 
apolipoproteins but did not induce lipid peroxidation [69, 72]. The apolipoprotein 
crosslinking was associated With decreased HDL ligand binding activity to fibroblasts but 
without any change in cholesterol efflux from the fibroblasts. Although CSE caused 
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apolipoprotein cross-linking, it did not induce lipid peroxidation of HDL. Therefore, 
modification of HDL by CSE did not decrease HDL-mediated cholesterol eftlux from 
macrophages. 
In summary, we demonstrated in the present study that CSE modified HDL into a 
form with decreased capacity to activate LCAT. It is conceivable that such modification 
might impair HDL's antiatherogenic function in reverse cholesterol transport in cigarette 
smokers. Three studies have found that LCAT activity is not decreased in cigarette 
smokers [58-60]. However, there has been no study examining possible HDL 
modification and functional impainnent of HDL in cigarette smokers. Therefore, data 
from this study warrant further research on HDL metabolism and function in cigarette 
smokers. 
CHAPTER Vll 
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The present study demon,strated that CSE modified HDL in vitro and the modified 
HDL had decreased capacity to activate LCAT. Although HDL oxidation has been 
studied intensively in vitro, there is no direct evidence that oxidized HDL exists in vivo. 
HDL has antioxidant activity and protects LDL against lipid oxidation [73, 74]. 
Therefore, it could be very difficult to demonstrate that oxidative modification of HDL 
occurs in vivo. However, glycosylation of HDL occurs in diabetic patients [75]. Glucose 
is an aldehyde and "reactive aldehydes" are present in cigarette smoke. Therefore, 
aldehyde addition can occur even though HDL is resistant to oxidation. Since cigarette 
smoke modifies HDL in vitro rapidly, it is possible that similar modification may occur 
in vivo and be detectable in heavy smokers. 
Two approaches might be used to detect modified HDL in cigarette smokers. 
First, autoantibodies against HDL modified by cigarette smoke could be measured in 
cigarette smokers. The human immune system may produce autoantibodies against 
modified HDL since modified HDL may be highly immunogenic, as in the case of 
oxidized LDL [76]. Two groups of human subjects would be needed for the study. One 
would be cigarette smokers and the other non-smoking control subjects. To quantify 
autoantibodies, a solid-phase radioimmunoassay that was developed to measure 
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autoantibodies against oxidized LDL [77] could be adapted. ln this assay, antigens, such 
as HDL modified by cigarette smoke in vitro, would be coated at the bottom of microtiter 
plate wells. After remaining binding sites are blocked with 2% BSA, serum dilutions 
from human subjects would be added in the wells for an overnight incubation. The 
antigen-antibody complexes would be then detected by adding an iodinated monoclonal 
antibody specific for human IgG, lgA, or lgM. To increase the sensitivity, 
immunoglobulins could be purified from human serum by the conventional method [78] 
and used in the assay. 
The second approach would be to conduct a sensitive functional test of HDL and 
compare the results from cigarette smokers with those from nonsmokers. We found in 
this study that LCAT activation capacity of HDL decreased when HDL was modified. 
Since HDL lost its LCAT activation capacity very rapidly upon the incubation with CSE, 
the functional test may be sensitive enough to detect a difference in LCAT activation 
capacity of HDL between cigarette smokers and the non-smoking control subjects. 
Because of its importance in reverse cholesterol transport, LCAT enzyme itself has been 
studied in cigarette smokers. Although cigarette smokers have less LCAT mass [79], their 
LCAT activity did not change compared to their nonsmoking counterparts [58-60]. The 
assay of LCAT activation capacity of HDL might be more appropriate than the LCAT 
activity assay in studying HDL-mediated reverse cholesterol transport in cigarette 
smokers.· 
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The present study did not examine the impact of HDL modification on the final 
step of reverse cholesterol transport, which is the transport of cholesterol back to the liver 
for disposal. The recent identification of a specific HDL receptor [13] makes this research 
possibility feasible in a future study. The identified HDL receptor is expressed in the liver 
and nonplacental steroidogenic tissues including ovary, adrenal gland, testis and 
mammary gland. The major function of the receptor is to facilitate selective delivery of 
cholesterol esters to the tissues, finislring the revers_e cholesterol transport by removal of 
HDL cholesterol from the circulation. Therefore, this HDL receptor is different from 
other HDL receptors expressed in fibroblasts and macrophages. These latter HDL 
receptors may be involved in facilitating cholesterol eftlux or intracellular signaling [80]. 
To measure selective cholesterol delivery via the liver HDL receptor, HDL (native or 
modified) can be radiolabelled with eH]-cholesteryl oleate and then incubated with 
hepatocytes. Following the incubation, cellular eH]-cholesterol and total cholesterol can 
be determined. 
Modification of HDL by cigarette smoke might result in the impairment of 
reverse cholesterol transport and reduce the protective effects of HDL against 
atherosclerosis in cigarette smokers. It is of practical importance to identify compounds 
that can inhibit HDL modification by cigarette smoke. In the present study, the 
antioxidant ascorbate was not effective. Although aminoguanidine and glutathione 
protected HDL from CSE-induced modification to a large extent, the concentrations were 
very high and not physiological. More importantly, each compound only provided limited 
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protection against CSE-mediated loss of LCAT activation capacity of HDL even at such 
high concentrations. To identify effective compounds that inhibit HDL modification by 
cigarette smoke, a better understanding of the mechanism of the modification is 
indispensable. Future study is in need to identify the toxic chemicals in cigarette smoke 
that are responsible for the modification of HDL. Only with that information, a strategy 
to inhibit this process can be developed. In the meantime, curtailment of cigarette 
smoking is recommended to decrease the risk of coronary heart disease. 
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